A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Buparlisib (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 01 Nov 2016 Results published in the Anticancer Research
- 11 Jan 2015 Status changed from active, no longer recruiting to completed.
- 22 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.